However, more recently the U.S. Food and Drug Administration (FDA) has approved the use of osimertinib also in first line for advanced NSCLC harboring common EGFR mutations (Mok et al. 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.